Peter the Bridge, Saint Petersburg, Russia

NEOMED Institute’s Laval Site: Ready to Welcome Life Sciences Companies to a World of Opportunities

2 June 2016|Announcement| 1 Comment
NEOMED-Institute-Laval-PEifert

PRESS RELEASE

Montreal, Quebec, June 2, 2016 – NEOMED announced today that its Laval site, a high-tech research and development facility dedicated to biologics and vaccines, is now open for business to companies seeking to rent cutting-edge lab and office space. Located in Laval’s Cité de la Biotech near Montreal, the NEOMED Institute combines innovation with an entrepreneurial culture, acting as an open-access drug discovery hub where all the players in the life sciences ecosystem interface and network to discover the drugs of tomorrow, for the benefit of patients and the entire biopharmaceutical community.
The biologics and vaccines facility – formerly GSK’s R&D site – spans over 60,000 sq. ft. with a 75% lab / 25% office distribution, and boasts state-of-the art laboratories operating under the highest standards, fully equipped for cell culture, molecular biology, immunology, purification, and analytical chemistry, including BL3 suites.
“The site has some of the best-in-class lab space for biologics, having been a North American leader in developing flu vaccines and antibodies,” commented Paul Lirette, President of GSK Canada Pharmaceuticals, Biotechnology Focus August/September 2015.

 

Benefits for resident companies:

  • Easy access to downtown Montreal & Pierre Elliot Trudeau Int’l Airport
  • Spacious cafeteria
  • Executive boardroom (20-person capacity) and multiple meeting rooms
  • 24/7 temperature monitoring for critical equipment
  • Sterilization & decontamination facilities
  • 2-way autoclave
  • In-house nitrogen
  • Purified water (RO) capacity of 2000 L/day
  • Waste management (domestic, chemical & biological) included

Click here to download a PDF with more information on suites currently available.

 

ABOUT THE NEOMED INSTITUTE
The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.

Share this

1 Comment

  • Jan Hamelink says:

    What about the capacity you have for microbial fermentation in your building? I believe that is worth mentioning as Well: the 4 X 20 L fermenters + all its capacity to control and monitor process parameters. But maybe I’ m biased…

  • Similar News

    image articles
    22 November 2017

    The NEOMED Institute is Attending the 23rd Annual BioEurope Partnering Conference

    Read complete news
    image articles
    20 September 2017

    NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

    Read complete news
    © 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia